Anavex Life Sciences - Bathi resik saben saham (EPS TTM) AVXL

The rolling net income per share reflects the R&D-stage losses of Anavex Life Sciences (AVXL), where the success of its Alzheimer's therapy would provide colossal scale. The current mark is -0.15, while the company currently lacks pricing power due to a lack of sales. The ultimate risk remains geopolitical tensions, which are hindering international certification and the logistics of biomaterials.
Anavex Corp - rincian analitis lan metrik utama (AVXL)

Anavex Life Sciences' total reliance on external CROs and CMOs makes its margins sensitive to the cost of contract research and manufacturing. This metric aggregates annual net income per share, allowing investors to assess real capital efficiency regardless of volatility by analyzing the rolling annual earnings per share as an indicator of business resilience to operating expenses.